VP, BOARD MEMBER, TECHIMMUNE
WHY: Lead investigator for TechImmune, which seeks to develop and commercialize a preemptive multi-antigen vaccine that could thwart various types of coronaviruses, including prevention of further COVID-19 outbreaks.
IN THE NEWS: Company backer Gavin Herbert Sr., of Allergan fame, estimates cost of $20M or so just to complete a Phase 1 clinical trial with humans. Big pharmaceutical firm could help complete the work and then take the product to market.
NOTABLE: A UCI professor and director of the Laboratory of Cellular and Molecular Immunology at the school’s Gavin Herbert Eye Institute.
